Understanding the Challenges of HER2+ Brain Metastases: New Perspectives

A panel of experts consisting of Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO recently participated in a Peer Exchange to discuss the latest advancements in the treatment of brain metastases in HER2-positive breast cancer.

During the discussion, O’Shaughnessy and McArthur shared insights on recent developments in this area. McArthur specifically highlighted findings from the HER2CLIMB trial, showing a notable survival benefit of the tucatinib-containing regimen, especially in patients with brain metastases. She emphasized the groundbreaking impact of this data on treatment strategies.

Furthermore, the experts discussed the results of the TUXEDO phase 2 trial, which explored the efficacy of trastuzumab deruxtecan (T-DXd) in patients with active brain metastases. The trial revealed an impressive progression-free survival of nearly 2 years in a high-risk population. Additionally, the I-ROSETTE study conducted by a Japanese group evaluated T-DXd in patients with leptomeningeal disease, demonstrating encouraging overall survival rates.

Overall, the panel highlighted the evolving landscape of HER2-positive breast cancer treatment, with new strategies addressing the needs of patients with brain and leptomeningeal involvement. The discussion shed light on the promising developments in this field.

The video synopsis of this Peer Exchange was AI-generated and reviewed by editorial staff.